Document:

Employment Agreement

 EXHIBIT 10.1 
 English Translation 
  
 INDEFINITE TERM 
 EMPLOYMENT AGREEMENT 
  
 BETWEEN THE UNDERSIGNED: 
  
 Alexion Europe SAS, a société par actions simplifiée, with a capital of EUR 37,000 registered with the Paris Registry of Commerce and
Companies under the number B 484251046, whose registered office is located at 54/56 avenue Hoche – Paris (75008), represented for the purposes hereof by Mr. David Keiser, in his capacity as President 
  
 hereinafter known as the “Company” 
  
 on the one hand, 
  
 AND: 
  
 Mr. Patrice Coissac, born on October 5, 1948, of French nationality, residing at 6, Square Alboni, 75016 Paris 

 
 hereinafter known as “Mr. Coissac” 
  
 on the other hand, 
  
 The Company and Mr. Coissac being collectively referred to hereinafter as the
“Parties”. 
  
 IT HAS BEEN AGREED AS FOLLOWS:

  
 ARTICLE 1: ENGAGEMENT 
  
 Mr. Coissac is hired by the Company for an indefinite term, as from the date of
signature of this Employment Agreement indicated at the end hereof (the “Signature Date”), as Operations Manager Europe subject to the results of a pre-hiring medical examination. 
  
 It is expressly agreed that Mr. Coissac’s engagement is subordinated to the
condition that he is fully free from any other work relationship or obligation to another employer and in particular, from any non-competition obligation relating to the Company’s activity. 

 ARTICLE 2: DUTIES 
  
 Mr. Coissac is engaged as Operations Manager Europe, in charge of Marketing, Sales and Distribution, Group XI of the applicable Collective Bargaining Agreement, with
Executive status. 
  
 As Operations Manager Europe, Mr. Coissac will,
consistent with the nature of the activity of the company: 
  

	 	•	 	elaborate the marketing strategy on the basis of directives given by the Company, in coordination with the parent company; 

  

	 	•	 	coordinate the activities of the marketing, sales and distribution departments on a pan European level; 

  

	 	•	 	consolidate and control the teams’ performance on the ground. 

  
 The parties agree that the list of duties mentioned above is not exhaustive, as the Company reserves the right to modify the duties, insofar as such modifications are
compatible with Mr. Coissac’s experience and skills, without such modifications being considered as modifications of his employment agreement, which is expressly acknowledged by Mr. Coissac by the signature hereof. 
  
 Mr. Coissac will report to the President of Alexion Pharmaceuticals, Inc. on a timely
basis and as determined by the Company and Alexion Pharmaceuticals, Inc. 
  
 ARTICLE 3: TRIAL PERIOD 
  
 The trial period is fixed at three
(3) months of effective work as from the date of engagement. 
  
 During this
period, each of the parties may terminate this Employment Agreement at any time, without indemnities or notice period. 
  
 ARTICLE 4: WORK PLACE 
  
 For the record, Mr. Coissac shall be based in the premises of the Company, currently located at 54/56 avenue Hoche in Paris (75008). 
  
 Mr. Coissac acknowledges that his place of work could be transferred to any other place in metropolitan France or Brussels, Belgium, if
the Company so requires. Mr. Coissac expressly acknowledges by the signature hereof, that any such transfer shall not be considered as a modification of his employment agreement. In the event of such a transfer, the Company and Mr. Coissac
will agree on an appropriate adjustment to keep Mr. Coissac economically whole for the period of such transfer, in particular from a personal income tax and social charges standpoint. Any proposed transfer of Mr. Coissac to another
location than metropolitan France or Brussels, Belgium will be the subject of a separate negotiation between the Parties. 

 Moreover, due to the nature of his duties, which implies a high level of mobility, and in view of the nature of the
Company’s activity, Mr. Coissac shall be required to make regular business trips, both in France and abroad (including Europe, USA, Asia), which he hereby expressly accepts. 
  
 ARTICLE 5: REMUNERATION 
  
 In consideration for the performance of his duties, Mr. Coissac shall receive an annual basic lump sum gross salary of EUR 170,000 (one hundred and seventy thousand
Euros), payable in twelve (12) monthly installments. 
  
 Mr. Coissac
shall also benefit from an individual incentive scheme as from the Company’s 2005/2006 fiscal year, subject to meeting the targets which shall be fixed at a later date and which shall be specified in an amendment to the present Employment
Agreement. Such bonus may equal (i) for the fiscal year 2005-2006, a maximum of EUR 110,000 (one hundred ten thousand Euros) and (ii) for each subsequent year, a maximum of 50% of Mr. Coissac’s annual base salary (based upon a
full 12 months of service) plus his total expatriation premium paid during such year as provided below, in the case of both (i) and (ii) as may be determined by the CEO and President of Alexion Pharmaceuticals, Inc. based on achievement of
objectives calculated at the level of Alexion Pharmaceuticals, Inc. and agreed to individual goals. 
  
 The annual incentive scheme includes the indemnity for legal paid holidays. 
  
 In consideration for the amount of travel which Mr. Coissac will be called upon to undertake in the course of his professional duties, the Company shall also pay to Mr. Coissac an expatriation premium,
calculated as provided in Appendix I hereto. 
  
 The Company will also pay
Mr. Coissac a signing bonus equal to EUR 20,000 gross (twenty thousand Euros) payable in two installments of EUR 10,000 (ten thousand Euros) on the Signature Date and April 1, 2006. 
  
 Mr. Coissac’s remuneration will be re-evaluated on an annual basis and adjusted at
the end of the fiscal year (July 31). The first such re-evaluation and adjustment shall be effective on August 1, 2006. 
  
 ARTICLE 6: WORKING TIME 
  
 In view of his level of remuneration, the nature of his duties and the actual conditions of their performance, which necessitate a large amount of self sufficiency in the organization of his work schedule and enable
him to have vast autonomy in decision making, it has been agreed that his gross salary is an all-inclusive compensation for his activities and is not related to the number of working hours that Mr. Coissac shall actually have to carry out in
order to complete his duties, since he has senior executive status. 

 ARTICLE 7: PAID VACATION 
  

Mr. Coissac’s rights to paid vacation shall be determined in accordance with the applicable legal and collective bargaining agreement provisions. 

 
 The dates of vacation absence of Mr. Coissac shall be determined by mutual agreement
between Mr. Coissac and the Company according to the needs of the activity of the Company. 
  
 ARTICLE 8: BUSINESS EXPENSES 
  
 The
Company shall reimburse Mr. Coissac for any reasonable expenses incurred in the performance of his duties, upon presentation of appropriate receipts, in accordance with the Company’s policy in force which may be modified at any time, and
of which Mr. Coissac agrees he has been informed. 
  
 For the purposes of the
foregoing, business class air travel by Mr. Coissac shall be considered reasonable. 
  
 ARTICLE 9: CAR ALLOWANCE 
  
 Mr. Coissac will be entitled to a car allowance in an approximate amount of EUR 1,000 (one thousand euros) gross per month, all as shall be determined by a separate agreement between Alexion and Mr. Coissac. 
  
 ARTICLE 10: SOCIAL COVERAGE 
  
 With regard to the application of laws on social security and pension and death and
disability schemes, the Parties agree to reciprocally comply with all statutory or contractual provisions, current or future, governing these matters. 
  
 Mr. Coissac shall benefit from all the complementary pension and death and disability regimes in force within the Company or that are put into effect in the future,
for employees of the same category. 
  
 In this respect, Mr. Coissac shall
contribute to these regimes by having his contributions deducted from his salary. 
  
 ARTICLE 11: ABSENCES, ILLNESS 
  
 Any foreseeable absence must be
authorized by the Company. 
  
 Moreover, in the event of illness or a force
majeure event, Mr. Coissac shall inform the Company as soon as possible, so that every useful measure may be taken to ensure that the activity is carried out. Mr. Coissac shall provide the appropriate justifications within a maximum
period of forty eight (48) hours. 

 ARTICLE 12: INVENTIONS 
  

Any inventions and improvements to inventions, designs or development of software, literary or artistic creations, whether protectible or not, made by Mr. Coissac
or to which he might have contributed during or at the time of his employment or the performance of his duties and any industrial property rights and related authors’ rights (droits d’auteur) shall be and shall remain the exclusive
property of the Company and shall be governed by the provisions of the Collective Bargaining Agreement. At the first demand of the Company, Mr. Coissac undertakes to sign any documents and perform all formalities that may be necessary for the
Company to obtain a patent or any other intellectual property protection relating to inventions, software, literary and artistic creations, discoveries and their improvements. 
  
 ARTICLE 13: PROFESSIONAL OBLIGATIONS 
  
 Mr. Coissac undertakes, both during the performance of this Employment Agreement and in particular, after its possible termination, for any reason whatsoever, to
keep absolutely confidential all the information of which he has knowledge or acquired during the performance of his duties, and not to disclose the identity of the suppliers, clients or partners of the Company to third parties. 
  
 Mr. Coissac undertakes not to disclose to any third parties both during the duration of
his Agreement with Company and after its possible termination, any of the projects, studies and creations made on behalf of the Company or the companies of the Group or on behalf of the clients of the Company or the Group. 
  
 During the entire term of this Employment Agreement, Mr. Coissac shall devote the
exclusivity of his services to the Company and cannot have any other professional obligation, even if this activity is not competitive with that of the Company, without the prior written agreement of the Company, subject to the following exception:
it has been agreed between the Parties that Mr. Coissac would remain Gérant and shareholder of BioPharmaConsult provided that (i) Mr. Coissac shall not perform any operational duties at BioPharmaConsult and (ii) his
position as Gérant or shareholder of such Company shall not be competitive with that of the Company and shall not interfere in any way with the performance of his duties pursuant to this Agreement. 
  
 ARTICLE 14: PROHIBITION OF ENTICEMENT 
  
 Mr. Coissac may not directly or through a third party without the prior written consent
of the Company for a period of one year after the end of this Employment Agreement, whatever the reason for the termination, offer any enticement to, solicit or hire - in whatever manner and in whatever title or capacity - any individual who was
during the one year period prior to the termination of this contract employed by the Company or during the three month period prior to the termination of this contract was involved in discussions with a view to being employed by the Company and to
whom the Company makes a written offer at the latest 3 months following such termination. 

 ARTICLE 15: RESTITUTION 
  

Mr. Coissac expressly undertakes to return or transfer, on the same day as the termination of his duties within the Company, for any reason whatsoever and without
the Company having to take any steps or give formal notice, all the documents, supports containing information and data, equipment or objects in his possession relating to the Company, the companies of the Group or any client, suppliers or third
parties, which he may have obtained in any capacity whatsoever, in the context of his activity within the Company. 
  
 Mr. Coissac undertakes, pursuant to the same terms, to return any equipment which would have been entrusted to him for carrying out his duties. 
  
 ARTICLE 16: TERMINATION OF AGREEMENT 
  
 As this Agreement is concluded for an indefinite term, either Party may terminate it at the
end of the notice period, in accordance with the applicable law and the Collective Bargaining Agreement, provided that prior notice of three (3) months is given, except that, no notice period is required in the case of gross or willful
misconduct or a force majeure event. 
  
 ARTICLE 17: APPLICABLE LAW

  
 This Agreement shall be governed by French law. For anything not set
forth herein, the Parties shall refer to the legal provisions in force as well as the provisions of the applicable collective bargaining agreement in force at the Company, which, at the date of this agreement and for information, is the National
Collective Bargaining Agreement for Pharmaceutical Industries. 
  
 Executed in
Paris, France, 
 On November 7, 2005 (the “Signature Date”) 
 In two originals, including one for each of the Parties. 
  

					
	/s/    DAVID W. KEISER        	 	 	 	/s/    PATRICE COISSAC        
	Mr. David W. Keiser	 	 	 	Mr. Patrice Coissac
	 For Alexion Europe SAS
	 	 	 	 

  
 The signatures of the Parties shall
be preceded by the handwritten words “Read and approved”. 

  
 APPENDIX I 

 
 Expatriation Premium 
 pursuant to article 81 A III of the General Tax Code 
  

	1.	Mr. Coissac will receive an indemnity pursuant to article 81 A III of the General Tax Code, based on the number of days which he will work outside France on behalf of the
Company. 

  

	2.	This indemnity shall be computed as follows, subject to the ceiling in article 3 below: 

  
 (i) Mr. Coissac will receive, in addition to his base salary, 300 Euros (three hundred Euros) gross per day of presence
in a foreign country, if such foreign country is located in Europe. 
  
 (ii) Mr. Coissac will be entitled to 600 Euros (six hundred Euros) gross per day spent outside Europe. 
  
 (iii) The day of departure and the day of arrival will each count for a full day. 
  
 Saturdays and Sundays spent abroad for the Company will each also count for one day. 
  
 (iv) One day will be added if Mr. Coissac stays abroad five days on end
without being in a position to revisit his home. 
  
 (v) The
total amount of the indemnity as computed above will be multiplied by two (2) if Mr. Coissac has stayed more than 45 days abroad in a given fiscal year of the Company. 
  

	3.	Whatever the total amount of the indemnity as computed above, Mr. Coissac’s total indemnity for days spent abroad in a given fiscal year of the Company shall not exceed
the gross amount of 50,000 Euros (fifty thousand Euros). 

  

	4.	The amount of the expatriation premium shall be indicated on Mr. Coissac’s pay slips. 

  

	5.	The indemnity shall be paid monthly as an advance. If at the end of the fiscal year in question the total amount of the advances of the expatriation indemnity to Mr. Coissac in
connection with such fiscal year exceeds the total amount of the indemnity to which Mr. Coissac is entitled pursuant to Articles 1 to 3 above for that year, the excess of the advances shall be repaid at the latest on the August 31
following the end of the fiscal year in question. 

  

	6.	Mr. Coissac shall be required to maintain and show to the Company all relevant documentary proof of such travel, including the purpose, duration and destination of each trip.

	7.	It is expressly agreed that in the event of a tax audit, Mr. Coissac shall bear the risk of any additional taxes, interest and/or penalties which may result therefrom, without
any liability for the Company or the Group in connection therewith. In connection with the foregoing, the Company recommends that Mr. Coissac keep all documentary proof in connection with his foreign travel. 

  

					
			
	/s/    DAVID W. KEISER        	 	 	 	/s/    PATRICE COISSAC        
	Mr. David W. Keiser	 	 	 	Mr. Patrice Coissac
	 For Alexion Europe SAS
	 	 	 	 

  
 The signatures of the Parties shall
be preceded by the handwritten words “Read and approved”.Severence Letter Agreement

 EXHIBIT 10.2 
 English Translation 
  
 [On
Alexion Pharmaceuticals, Inc. letterhead] 
  
 November 7, 2005 
  
 Mr. Patrice Coissac 
 6, square Alboni 
 F-75016 Paris 
 France 
  
 Dear Patrice, 
  
 Further to our discussions, we would like to confirm the following points: 
  
 1- In the event that both (a) Alexion Europe SAS (the “Company”) terminates
your employment agreement unilaterally for reasons other than a personal cause (or you resign from your employment agreement in accordance with part 5 of this letter agreement), and (b) Alexion Pharmaceuticals, Inc. as shareholder of the
Company concurrently or thereafter removes you as President of the Company for reasons other than a personal cause, then we shall cause the Company to pay to you a lump sum contractual indemnity, as damages, equal to 12 (twelve) months of
Remuneration as defined below (regardless of any severance payment provided by the law or the Collective Bargaining Agreement). For the purpose of this letter agreement, “Remuneration” shall be defined as your base gross monthly salary
plus 1/12 of your total expatriation premium accrued during the most recent 12-month period plus 1/12 of the average annual bonus over the most recent 2-year period (or in the event your employment agreement is terminated and you continue as
President of the Company, the same amount, pursuant to part 2 below). 
  
 In the
event of a change of control of the Company entailing (i) if you have not resigned from your employment agreement in accordance with part 5 of this letter agreement, the termination of your employment agreement by the Company (or by you for
demonstrable reasons of breach of professional ethics by the acquiror), and (ii) the termination of your mandat social as President of the Company by the acquiror (or by you for demonstrable reasons of breach of professional ethics by
the acquiror), all in the absence of a basis for termination for personal cause, the above-mentioned contractual indemnity by the Company would be increased to 18 (eighteen) months of Remuneration (regardless of any severance payment provided by the
law or the Collective Bargaining Agreement). 
  
 Such indemnity will be paid
within a 30-day period following the date of termination of your employment agreement. 

 2- In the event that you resign from your employment agreement but you remain President of the Company (in the absence of
a termination covered by part 1 above), it is agreed that your remuneration as President of the Company shall be fixed by the undersigned in its capacity as sole shareholder of the Company at the same gross amount as the gross amount of your
remuneration pursuant to such employment agreement. 
  
 3- It is agreed that you
undertake, both during the performance of your mandat social and in particular, after its possible termination, for any reason whatsoever, to keep absolutely confidential all the information of which you shall have knowledge or which you
shall have acquired during the performance of your duties, and not to disclose the identity of the suppliers, clients or partners of the Company to third parties. 
  
 You undertake not to disclose to any third parties both during the duration of your mandat social at the Company and after its
possible termination, any of the projects, studies and creations made on behalf of the Company or the companies of the Group or on behalf of the clients of the Company or the Group. 
  
 During the entire term of your mandat social, you shall devote the exclusivity of your services to the Company and cannot have any
other professional obligation, even if this activity is not competitive with that of the Company, without the prior written agreement of the Company, subject to the following exception: it has been agreed between us that you would remain
Gérant and shareholder of BioPharmaConsult provided that (i) you shall not perform any operational duties at BioPharmaConsult and (ii), as provided below, your position as Gérant or shareholder shall not be
competitive with that of the Company and shall not interfere in any way with the performance of your mandat social at the Company. 
  
 It is furthermore agreed that you shall not directly or through a third party without the prior written consent of the Company for a period of one year after the end of
your mandat social, whatever the reason for the termination, offer any enticement to, solicit or hire - in whatever manner and in whatever title or capacity - any individual (i) who was during the one year period prior to the termination
of your mandat social employed by the Company, or (ii) who was during the 3-month period prior to the termination of your mandat social involved in discussions with a view to being employed by the Company and to whom the Company
makes a written offer at the latest 3 months following such termination. 
  
 You
shall not during the term of your mandat social, and during a one-year period after its end, engage in any act that is directly or indirectly competitive with the Company’s business or that could be to its detriment. 
  
 In particular, in view of your duties within the Company, you acknowledge that the Company
has a legitimate interest, both during the term of your mandat social and after its termination, that you do not compete with the Company and/or the shareholder and/or affiliated companies of the Company (together the “Group”) in
its sector of actual or planned activity at the date of termination of your mandat social. Therefore, during the term of your mandat social and for a period of one year as from its end, for any reason whatsoever and whichever party
takes the initiative of the termination, you undertake not to: 
  

	 	•	 	work on behalf of a client of the Company or the Group or to collaborate indirectly with a client or a prospective client of the Company or the Group with a view to performing an
activity in competition with the activity of the Company or the Group; 

  

 Page 2 

	 	•	 	enter into the service of a company that is created, in the process of being created, or to be created, whose activity would be in direct competition with the activity of the
Company or the Group; 

  

	 	•	 	take an interest, directly or indirectly, in such a company, in any capacity or in any way whatsoever, and in particular, as an employee, non-salaried worker, personal company,
partner, corporate officer, limited partner, etc. 

  
 This
prohibition shall apply throughout the territory of France and Europe. At the end of your mandat social and for the above-mentioned period of one year, we shall cause the Company to pay you a total financial consideration for this
non-competition obligation (the “Non-Competition Financial Consideration”), as follows: 
  

	 	(a)	in the event of (i) your resignation from your mandat social as President of the Company or (ii) the termination of your mandat social as President of the
Company by Alexion Pharmaceuticals, Inc. as shareholder of the Company for a reason of personal cause, the Non-Competition Financial Consideration shall be equal to 33% multiplied by 12 multiplied by the Remuneration, 

  
 divided into 12 equal monthly installments; or 
  

	 	(b)	in the event of termination of your mandat social as President of the Company by Alexion Pharmaceuticals, Inc. as shareholder of the Company for reasons other than personal
cause (and other than as provided in subparagraph (c) below), the Non-Competition Financial Consideration shall be equal to the greater of : 

  

	 	(i)	33% multiplied by 12 multiplied by the Remuneration, or 

  

	 	(ii)	((the lower of: (12 multiplied by the Remuneration) or 366,000 euros) less 182,000 euros) multiplied by 96%, 

  
 divided into 12 equal monthly installments; or 
  

	 	(c)	in the event of termination of your mandat social as President of the Company by Alexion Pharmaceuticals, Inc. as shareholder of the Company for reasons other than personal
cause, which reasons are related to a change in control of the Company (or you resign from your functions as President of the Company for demonstrable reasons of breach of professional ethics by the acquiror), the Non-Competition Financial
Consideration shall be equal to the greater of : 

  

	 	(i)	33% multiplied by 18 multiplied by the Remuneration, or 

  

	 	(ii)	((the lower of: (18 multiplied by the Remuneration) or 366,000 euros) less 182,000 euros) multiplied by 86%, 

  
 divided into 12 equal monthly installments. 
  
 Notwithstanding the foregoing, it is expressly agreed that, in the situations referred to in
subparagraph (a) above, we may release you from this non-competition obligation within a 

  

 Page 3 

 
period of one (1) month following the termination of your mandat social, in which case the Non-Competition Financial Consideration shall be zero.

  
 Examples of applications of the formula in subparagraphs (b) and
(c) above, in each case using a hypothetical Remuneration of 27,500 euros, are set forth in Annex 1 hereto, it being understood that such Annex 1 shall be for illustrative purposes only and shall not have contractual value. 
  
 4- It is expressly understood and agreed that in no circumstances shall you have a right to
any termination indemnity other than as expressly provided in part 1 of this letter agreement nor shall you have any right to any remuneration in connection with a non-competition obligation other than as expressly provided in part 3 of this letter
agreement. 
  
 5- In addition, in the event that the Assedic expressly refuses
your admission to the general unemployment regime, you shall resign from your employment agreement, and in consideration thereof, the Company will subscribe to a private insurance fund for you, GSC, in the category 6H, option 18 months. 

 
 By your acceptance of this letter, you agree to keep it and its contents confidential vis
à vis third parties. 
  
 Please indicate your acceptance of and agreement
with this letter by signing and returning to us the attached copy hereof. 
  

			
	 Sincerely,

	
	 Alexion Pharmaceuticals, Inc.

		
	By:	 	/s/    DAVID W. KEISER        
	 	 	David W. Keiser
	 	 	President and Chief Operating Officer

  

	
	 Accepted and agreed by:

	
	/s/    PATRICE COISSAC        
	Patrice Coissac
	
	 Date: November 7, 2005

  

 Page 4 

 Annex 1 
  
 For illustrative purposes only, an application of the formula in part 3(b) to the hypothetical case of a Remuneration of 27,500 euros would
be as follows: 
  
 The greater of: 
  

	 	(iii)	33% multiplied by 12 multiplied by 27,500 euros = 108,900 euros, or 

  

	 	(iv)	((the lower of: (12 multiplied by 27,500 euros = 330,000 euros) or 366,000 euros, i.e. 330,000 euros) less 182,000 euros = 148,000 euros) multiplied by 96% = 142,080 euros,

  
 i.e. 142,080 euros, 
  
 divided into 12 equal monthly installments of 11,840 euros. 
  
 *** 
  
 Also for illustrative purposes only, an application of the formula in part 3(c) to the hypothetical case of a Remuneration of 27,500 euros
would be as follows: 
  
 The greater of: 
  

	 	(ii)	33% multiplied by 18 multiplied by 27,500 euros = 163,350 euros, or 

  

	 	(ii)	((the lower of: (18 multiplied by 27,500 euros = 495,000 euros) or 366,000 euros, i.e. 366,000 euros) less 182,000 euros = 184,000 euros) multiplied by 86% = 158,240 euros,

  
 i.e. 163,350 euros, 
  
 divided into 12 equal monthly installments of 13,612.50 euros. 
  

 Page 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]